ROIVANT SCIENCES LTD

Insightful look at Roivant’s insider buy‑sell rhythm: how Mayukh Sukhatme’s $3.85 dip buys and $37 sell‑outs reveal short‑term tactics and long‑term confidence.

ROIVANT Sciences insider trade: CEO buys at $3.85, sells at $36.23, capturing $32/share profit while staying net‑neutral—an insight into portfolio tactics, not a sell signal.

Insider buys 17,750 Roivant shares while selling options and shares, signaling confidence in its R&D pipeline and long‑term upside.

Roivant insider sale: Keith Mancaster off‑loads 600,000 shares on June 26, 2026 at $35, dropping only slightly below market. Explore what this signals for investors.

QVT Financial LP’s June 2026 sell‑off of 1.3 m Roivant shares signals strategic rebalancing, not a loss, as the stock stays below its 52‑week high.

ROIVANT insider buys: CEO Eric Venker’s 200k-share purchase at $34.06 signals confidence in the company’s high‑growth pipeline, but frequent Rule 10b5‑1 moves hint at potential volatility for investors.

Investor insights on Roivant Sciences insider moves: Venker’s strategic selling and buying around $32 shows liquidity plans amid bullish growth and promising trial data.

Explore how Roivant Sciences’ CEO’s buy‑sell‑exercise strategy balances liquidity with long‑term stake, and what it means for investors.

Roivant insider moves show routine vesting, not distress—Oren Ilan’s share activity confirms long‑term confidence amid a solid pipeline and upside potential.

Epperly Melissa B’s recent insider purchase signals steady confidence in Roivant Sciences, hinting at potential upside as the company advances its oncology pipeline.